^
    9d
    A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, Children's Oncology Group | Trial completion date: Feb 2030 --> Dec 2027 | Trial primary completion date: Apr 2027 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    SurVaxM (SVN53-67/M57-KLH peptide vaccine)
    17d
    A layered double hydroxide nanocarrier enables YM155 delivery-induced PANoptosis and immunogenic activation in hepatocellular carcinoma. (PubMed, RSC Adv)
    Further immune profiling revealed enhanced dendritic cell maturation, pro-inflammatory macrophage polarization, and increased cytotoxic CD8+Granzyme B+ T-cell activation within the tumor microenvironment. Collectively, this LDH-based nanotherapeutic strategy enhances YM155 efficacy by coupling Survivin inhibition with PANoptosis activation and ICD-associated immune stimulation, providing a promising platform for hepatocellular carcinoma therapy.
    Journal
    |
    CD8 (cluster of differentiation 8) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • CASP8 (Caspase 8) • GZMB (Granzyme B) • CALR (Calreticulin) • NLRP3 (NLR Family Pyrin Domain Containing 3) • ANXA5 (Annexin A5)
    |
    sepantronium bromide (PC-002)
    25d
    Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial. (PubMed, Nat Commun)
    Survivin-specific immune responses occur in 62.5% of tested patients and correlate with clinical benefit. The combination demonstrates tolerability and sustained clinical activity.
    P1/2 data • Journal
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • maveropepimut-S (MVP-S)
    27d
    SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: May 2026 --> Dec 2026
    Trial completion date
    |
    lenalidomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    29d
    PANACEA: MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=38, Not yet recruiting, Marker Therapeutics, Inc. | Trial completion date: Dec 2027 --> Sep 2028 | Trial primary completion date: Sep 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    1m
    Whole-genome doubling drives immune evasion by silencing antigen presentation. (PubMed, Cancer Cell)
    PRC2 inhibition preferentially suppresses WGD+ tumor growth, enhances antigen presentation, and CD8+ T cell infiltration. Our results underscore metabolic and epigenetic alterations as critical drivers of WGD-associated immune escape.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    sepantronium bromide (PC-002)
    2ms
    Testing the SurVaxM Vaccine for Lung Cancer Prevention (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2027 --> Sep 2029 | Initiation date: Feb 2026 --> Jun 2026 | Trial primary completion date: Sep 2027 --> Mar 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)
    2ms
    MRI of combination immunotherapy in an epithelial ovarian cancer preclinical model. (PubMed, Npj Imaging)
    We studied MRI immune cell tracking in a murine model of ovarian cancer using a clinically relevant treatment combination of DPX-Survivac, anti-PD-1, and an intermittent low dose of Cyclophosphamide (CPA). The density of SPIO-labeled myeloid and CD8+ T cells in tumors was higher in the treatment group than in the control group. This study provides insights into how MRI can be used in concert with biological assays to study how immunotherapy and chemotherapy combinations exert their antitumor effects.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    cyclophosphamide • maveropepimut-S (MVP-S)
    2ms
    Dual-targeted approaches in cancer therapy: integrating siRNA and chemotherapy for improved outcomes. (PubMed, 3 Biotech)
    Early clinical candidates, such as EZN-3042 and ALN-VSP, achieved target engagement and biological activity, while limitations included variable tumour uptake, dose-limiting toxicities, and complex pharmacokinetic behaviour. Translation to clinical practice will depend on optimised delivery platforms, reproducible pharmacokinetic/pharmacodynamic synchronisation, and rigorous evaluation of safety and off-target effects. Overall, current evidence highlights substantial potential for siRNA-drug co-delivery while emphasizing key challenges to overcome in achieving durable clinically meaningful outcomes.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • MUC1 (Mucin 1) • BIRC5 (Baculoviral IAP repeat containing 5)
    2ms
    NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Mar 2026 --> Jun 2026
    Trial completion date
    |
    temozolomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)